These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39207799)

  • 21. Impact of anti-VEGF treatment on development of proliferative diabetic retinopathy in routine clinical practice.
    Moshfeghi AA; Khurana RN; Moini H; Sherman S; Reed K; Boucher N; Rahimy E
    BMC Ophthalmol; 2024 May; 24(1):229. PubMed ID: 38822279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.
    Sun JK; Glassman AR; Beaulieu WT; Stockdale CR; Bressler NM; Flaxel C; Gross JG; Shami M; Jampol LM;
    Ophthalmology; 2019 Jan; 126(1):87-95. PubMed ID: 30096354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
    Diabetic Retinopathy Clinical Research Network*
    JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema: The Vitrectomy in Diabetic Macular Oedema (VIDEO) Randomized Clinical Trial.
    Maguire MJ; Laidlaw A; Hammond C; Muqit MMK; Steel D; Dinah C; Lee E; Hillier R; Almeida G; Hussain R; Gordon-Bennet P; Hughes E; Alexander P; Vaideanu-Collins D; Jackson T
    JAMA Ophthalmol; 2024 Sep; 142(9):837-844. PubMed ID: 39115867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial.
    Abd Elhamid AH; Mohamed AAEA; Khattab AM
    BMC Ophthalmol; 2020 Apr; 20(1):130. PubMed ID: 32252674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
    Martinez-Zapata MJ; Salvador I; Martí-Carvajal AJ; Pijoan JI; Cordero JA; Ponomarev D; Kernohan A; Solà I; Virgili G
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD008721. PubMed ID: 36939655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitreous Fibronectin and Fibrinogen Expression Increased in Eyes With Proliferative Diabetic Retinopathy After Intravitreal Anti-VEGF Therapy.
    Wei Q; Zhang T; Jiang R; Chang Q; Zhang Y; Huang X; Gao X; Jin H; Xu G
    Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5783-5791. PubMed ID: 29117316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy.
    Parikh RN; Traband A; Kolomeyer AM; VanderBeek BL; Kim BJ; Maguire AM; Brucker AJ
    Am J Ophthalmol; 2017 Apr; 176():194-202. PubMed ID: 28130042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-VEGF Therapy for Persistent Neovascularization after Complete Panretinal Photocoagulation in Proliferative Diabetic Retinopathy.
    Mehanna CJ; Abdul Fattah M; Haddad S; Tamim H; Ghazi N; Salti H
    Ophthalmol Retina; 2019 Jun; 3(6):473-477. PubMed ID: 31174668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    ; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
    JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.
    Chatziralli I; Dimitriou E; Theodossiadis G; Kazantzis D; Theodossiadis P
    Acta Diabetol; 2020 Oct; 57(10):1219-1225. PubMed ID: 32472172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment.
    Dong F; Yu C; Ding H; Shen L; Lou D
    Medicine (Baltimore); 2016 Feb; 95(8):e2731. PubMed ID: 26937902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial.
    Preti RC; Ramirez LM; Monteiro ML; Carra MK; Pelayes DE; Takahashi WY
    Br J Ophthalmol; 2013 Jul; 97(7):885-9. PubMed ID: 23686001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.
    Simunovic MP; Maberley DA
    Retina; 2015 Oct; 35(10):1931-42. PubMed ID: 26398553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal anti-vascular endothelial growth factor versus panretinal LASER photocoagulation for proliferative diabetic retinopathy: a systematic review and meta-analysis.
    Yates WB; Mammo Z; Simunovic MP
    Can J Ophthalmol; 2021 Dec; 56(6):355-363. PubMed ID: 33631120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infographic: Ranibizumab plus panretinal photocoagulation (PRP) versus PRP alone for high-risk proliferative diabetic retinopathy (PDR): the PROTEUS study.
    Yusuf IH; Henein C; Sivaprasad S
    Eye (Lond); 2024 Aug; 38(Suppl 2):43-44. PubMed ID: 37085718
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy.
    Shin YW; Lee YJ; Lee BR; Cho HY
    Korean J Ophthalmol; 2009 Dec; 23(4):266-72. PubMed ID: 20046686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Antoszyk AN; Glassman AR; Beaulieu WT; Jampol LM; Jhaveri CD; Punjabi OS; Salehi-Had H; Wells JA; Maguire MG; Stockdale CR; Martin DF; Sun JK;
    JAMA; 2020 Dec; 324(23):2383-2395. PubMed ID: 33320223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial.
    Beaulieu WT; Bressler NM; Melia M; Owsley C; Mein CE; Gross JG; Jampol LM; Glassman AR;
    Am J Ophthalmol; 2016 Oct; 170():206-213. PubMed ID: 27523491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.